{"id":883130,"date":"2025-09-07T18:28:09","date_gmt":"2025-09-07T22:28:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/"},"modified":"2025-09-07T18:28:09","modified_gmt":"2025-09-07T22:28:09","slug":"dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/","title":{"rendered":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK and WALTHAM, Mass., Sept.  07, 2025  (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.<\/p>\n<p>\n        <strong>Investor Webcast &amp; Conference Call Information<\/strong><br \/>\n        <br \/>To access the live conference call by phone, please register\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aXHlX9XD2OZ12ahnPCMd02g8E5yGwlFoEz3fxrzcct2-TiJpD0VBn9tWFSRdl_azerzA9Qx31ngXeSN4QVYEe6j_bQ_rN3WPAuik_pqqfvKmCtn7bM7NUDquw_DL9KBtYLvRdD4sm-L_YhaOAiUdO-CFX-xdxl1eWoMIYv2l5x0=\" rel=\"nofollow\" target=\"_blank\">here<\/a>.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0<\/p>\n<p>A live webcast may be accessed through the Investors and Media section of the Company\u2019s website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B08zMTA_QIPRfoOudFJs44PIFAdJ7uZERBpwZKWCN9p_v7Bvto2qoqiSVsuC7haxHxLVA5xDQWi7HF4RJZVHG4SGxZJgpRkfCAnWIn4N38g=\" rel=\"nofollow\" target=\"_blank\">www.dianthustx.com<\/a>. Following the call, a replay will be available at the same location.<\/p>\n<p>\n        <strong>About Dianthus Therapeutics<\/strong><br \/>\n        <br \/>Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.<\/p>\n<p>To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B08zMTA_QIPRfoOudFJs41ka_rc3l9RIA8zZo1c418LIJ0OCq6wLOs8leiwW1KYQS9XeGGncAGdRwvLWhZcFzAxFDLuayR7ggNVBW0v16p8=\" rel=\"nofollow\" target=\"_blank\">www.dianthustx.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W2vTMvmbO65bbVHoZaIurlTtyR5L3A19qrsHIoZ5iidvnoUOSeegY6uzzQIW8DeB4ipQ0Ep811SPntBvmAQdnE7nBnC8YWdg-gK_tmvm2YDytcHgWmSRuUWVDWyhfB2H4A28Xsq-Hee1Xiu33RWwNw==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.\u00a0<\/p>\n<p>\n        <strong>Contact <\/strong><br \/>\n        <br \/>Jennifer Davis Ruff<br \/>Dianthus Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yLm32yIRajK8CqHWjzRpjZz8Rvh-wswRgixKYFV1rmfoTKtRdOY8-5p3wp7RzV39L7U1EfjdQdQzxAxr9HT08_Ttr5WXVWsgKfHWfbbEDFiWVQ4LBsh_zM8FK6F5spcF\" rel=\"nofollow\" target=\"_blank\">jdavisruff@dianthustx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWE0ZGU4NDItYmZmMS00NWZkLWIzNDgtYTYzNWY1YjllYmRmLTEyNzE5MzktMjAyNS0wOS0wNy1lbg==\/tiny\/Dianthus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast &amp; Conference Call Information To access the live conference call by phone, please register\u00a0here.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0 A live webcast may be accessed through the Investors and Media section of the Company\u2019s website,\u00a0www.dianthustx.com. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-883130","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast &amp; Conference Call Information To access the live conference call by phone, please register\u00a0here.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0 A live webcast may be accessed through the Investors and Media section of the Company\u2019s website,\u00a0www.dianthustx.com. &hellip; Continue reading &quot;Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-07T22:28:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis\",\"datePublished\":\"2025-09-07T22:28:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/\"},\"wordCount\":244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/\",\"name\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=\",\"datePublished\":\"2025-09-07T22:28:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/","og_locale":"en_US","og_type":"article","og_title":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - Market Newsdesk","og_description":"NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast &amp; Conference Call Information To access the live conference call by phone, please register\u00a0here.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0 A live webcast may be accessed through the Investors and Media section of the Company\u2019s website,\u00a0www.dianthustx.com. &hellip; Continue reading \"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-07T22:28:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis","datePublished":"2025-09-07T22:28:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/"},"wordCount":244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/","name":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=","datePublished":"2025-09-07T22:28:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNDczOCM3MTM0MDk4IzIyNjAzODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-results-from-phase-2-magic-trial-of-claseprubart-dnth103-in-generalized-myasthenia-gravis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/883130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=883130"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/883130\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=883130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=883130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=883130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}